BNT162b2疫苗在系统性红斑狼疮患者中诱导的针对SARS-CoV-2变异株的体液和细胞免疫应答
这项前瞻性研究纳入126例系统性红斑狼疮(SLE)患者,评估BNT162b2疫苗接种后的疾病活动性和SARS-CoV-2特异性免疫应答。研究发现疫苗耐受良好且未观察到BILAG和SLEDAI评分显著变化;霉酚酸酯(MMF)和甲氨蝶呤(MTX)治疗与抗体应答大幅降低独立相关,基线总IgG水平和初始B细胞频率与抗刺突抗体应答正相关。
要点
- BNT162b2在SLE患者中耐受良好,未导致疾病活动性评分显著变化。
- MMF和MTX治疗与BNT162b2抗体应答大幅降低独立相关。
- 基线总IgG水平、初始B细胞频率和SARS-CoV-2特异性T细胞应答与抗体应答正相关。
核心结论
- MMF、MTX和基线体液免疫状态差(尤其是低初始B细胞频率)与BNT162b2 mRNA抗体应答受损独立相关,提示部分SLE患者可能需要调整疫苗方案和随访。
研究设计与样本
- 前瞻性研究,纳入126例SLE患者,从疫苗第一剂至第二剂后第15天记录疾病活动和临床评估。
主要发现
- BNT162b2耐受良好,研究期间活动性和非活动性SLE患者的BILAG和SLEDAI评分无统计学显著变化。
- MMF治疗与抗体应答大幅降低相关(β=-78,p=0.007),MTX治疗也与抗体应答大幅降低相关(β=-122,p<0.001)。
- 抗刺突抗体应答与基线总免疫球蛋白G血清水平(β=2,p=0.018)和初始B细胞频率(β=2.5,p=0.003)正相关,与SARS-CoV-2特异性T细胞应答也呈正相关(r=0.462,p=0.003)。
- 在应答者中,针对携带E484K突变的变异株的血清中和活性下降,但在多数患者中仍可检测到。
临床怎么用
- 对于接受MMF或MTX治疗或基线初始B细胞频率低的SLE患者,应考虑其BNT162b2抗体应答可能受损,可能需要调整疫苗方案和加强随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Our aim was to evaluate systemic lupus erythematosus (SLE) disease activity and SARS-CoV-2-specific immune responses after BNT162b2 vaccination. METHODS: In this prospective study, disease activity and clinical assessments were recorded from the first dose of vaccine until day 15 after the second dose in 126 patients with SLE. SARS-CoV-2 antibody responses were measured against wild-type spike antigen, while serum-neutralising activity was assessed against the SARS-CoV-2 historical strain and variants of concerns (VOCs). Vaccine-specific T cell responses were quantified by interferon-γ release assay after the second dose. RESULTS: BNT162b2 was well tolerated and no statistically significant variations of BILAG (British Isles Lupus Assessment Group) and SLEDAI (SLE Disease Activity Index) scores were observed throughout the study in patients with SLE with active and inactive disease at baseline. Mycophenolate mofetil (MMF) and methotrexate (MTX) treatments were associated with drastically reduced BNT162b2 antibody response (β=-78, p=0.007; β=-122, p<0.001, respectively). Anti-spike antibody response was positively associated with baseline total immunoglobulin G serum levels, naïve B cell frequencies (β=2, p=0.018; β=2.5, p=0.003) and SARS-CoV-2-specific T cell response (r=0.462, p=0.003). In responders, serum neutralisation activity decreased against VOCs bearing the E484K mutation but remained detectable in a majority of patients. CONCLUSION: MMF, MTX and poor baseline humoral immune status, particularly low naïve B cell frequencies, are independently associated with impaired BNT162b2 mRNA antibody response, delineating patients with SLE who might need adapted vaccine regimens and follow-up.
引用
- Moyon Q, Sterlin D, Miyara M, et al. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Ann Rheum Dis. 2021. PMID: 34607791. doi:10.1136/annrheumdis-2021-221097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。